{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:07:06Z","timestamp":1790795226665,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,3,21]],"date-time":"2018-03-21T00:00:00Z","timestamp":1521590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.tranon.2018.03.012","type":"journal-article","created":{"date-parts":[[2018,4,24]],"date-time":"2018-04-24T09:24:41Z","timestamp":1524561881000},"page":"779-785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma"],"prefix":"10.1016","volume":"11","author":[{"given":"Xiaofang","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jietian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9396-2414","authenticated-orcid":false,"given":"Xiaofei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2018.03.012_bb0005","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/j.mayocp.2015.07.005","article-title":"Hodgkin lymphoma: diagnosis and treatment","volume":"90","author":"Ansell","year":"2015","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.tranon.2018.03.012_bb0010","doi-asserted-by":"crossref","first-page":"768","DOI":"10.12688\/f1000research.8301.1","article-title":"Recent advances in the management of Hodgkin lymphoma","volume":"5","author":"Villasboas","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.tranon.2018.03.012_bb0015","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00066-016-1050-4","article-title":"Checkpoint inhibitors and radiation treatment in Hodgkin's lymphoma : New study concepts of the German Hodgkin Study Group","volume":"193","author":"Baues","year":"2017","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.tranon.2018.03.012_bb0020","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1100340","article-title":"ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned","volume":"365","author":"Viviani","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tranon.2018.03.012_bb0025","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/968212","article-title":"Clinical options in relapsed or refractory Hodgkin lymphoma: An updated review","volume":"2015","author":"Fedele","year":"2015","journal-title":"J Immunol Res"},{"key":"10.1016\/j.tranon.2018.03.012_bb0030","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1517\/17425255.2015.1007950","article-title":"Brentuximab vedotin for treating Hodgkin\u2019s lymphoma: an analysis of pharmacology and clinical efficacy","volume":"11","author":"Illes","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.tranon.2018.03.012_bb0035","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1586\/14737140.2016.1121812","article-title":"Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab","volume":"16","author":"Villasboas","year":"2016","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.tranon.2018.03.012_bb0040","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s12185-017-2181-9","article-title":"Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation","volume":"106","author":"Onizuka","year":"2017","journal-title":"Int J Hematol"},{"key":"10.1016\/j.tranon.2018.03.012_bb0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","article-title":"Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway","volume":"21","author":"Ohaegbulam","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.tranon.2018.03.012_bb0050","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/ni1443","article-title":"The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection","volume":"8","author":"Sharpe","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.tranon.2018.03.012_bb0055","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"10.1016\/j.tranon.2018.03.012_bb0060","first-page":"400","article-title":"Nivolumab as first line monotherapy for advanced non-small cell lung cancer: could we replace first line chemotherapy with immunotherapy?","volume":"3","author":"West","year":"2014","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.tranon.2018.03.012_bb0065","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.2146\/ajhp150235","article-title":"Nivolumab for second-line treatment of metastatic squamous non-small-cell lung cancer","volume":"72","author":"Rounds","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.tranon.2018.03.012_bb0070","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrclinonc.2015.184","article-title":"Nivolumab\u2014an effective second-line treatment for NSCLC","volume":"12","author":"Romero","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.tranon.2018.03.012_bb0075","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tranon.2018.03.012_bb0080","article-title":"PD-L1 and survival in solid tumors: A meta-analysis","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2018.03.012_bb0085","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tranon.2018.03.012_bb0090","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1097\/MPH.0000000000000703","article-title":"Nivolumab in the treatment of refractory pediatric Hodgkin lymphoma","volume":"39","author":"Foran","year":"2017","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.tranon.2018.03.012_bb0095","doi-asserted-by":"crossref","first-page":"434","DOI":"10.5732\/cjc.014.10122","article-title":"Immune checkpoint inhibitors in clinical trials","volume":"33","author":"Sharon","year":"2014","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.tranon.2018.03.012_bb0100","doi-asserted-by":"crossref","first-page":"8315","DOI":"10.18632\/oncotarget.14174","article-title":"Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma","volume":"8","author":"Jiang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2018.03.012_bb0105","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.cca.2017.02.005","article-title":"PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients","volume":"469","author":"Xia","year":"2017","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.tranon.2018.03.012_bb0110","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/ijc.30552","article-title":"PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy","volume":"140","author":"Chen","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.tranon.2018.03.012_bb0115","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.tranon.2018.03.012_bb0120","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1093\/annonc\/mdx003","article-title":"PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer","volume":"28","author":"Tsao","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.tranon.2018.03.012_bb0125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cyto.2011.06.004","article-title":"Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines","volume":"56","author":"Chen","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.tranon.2018.03.012_bb0130","first-page":"2367","article-title":"High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial","volume":"28","author":"Rossille","year":"2014"},{"key":"10.1016\/j.tranon.2018.03.012_bb0135","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/0272989X8400400203","article-title":"Statistical approaches to the analysis of receiver operating characteristic (ROC) curves","volume":"4","author":"Mcneil","year":"1984","journal-title":"Med Decis Making"},{"key":"10.1016\/j.tranon.2018.03.012_bb0140","first-page":"104","article-title":"Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications","volume":"26","author":"Zheng","year":"2014","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.tranon.2018.03.012_bb0145","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejca.2016.03.002","article-title":"High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis","volume":"59","author":"Finkelmeier","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.tranon.2018.03.012_bb0150","first-page":"529","article-title":"Levels of programmed death-1 and programmed death ligand-1 in the peripheral blood of patients with oral squamous cell carcinoma and its clinical implications","volume":"33","author":"Zhang","year":"2015","journal-title":"Hua Xi Kou Qiang Yi Xue Za Zhi"},{"key":"10.1016\/j.tranon.2018.03.012_bb0155","first-page":"102","article-title":"The level of soluble programmed death-1 in peripheral blood of patients with lung cancer and its clinical implications","volume":"35","author":"Xing","year":"2012","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"10.1016\/j.tranon.2018.03.012_bb0160","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00432-016-2184-6","article-title":"Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer","volume":"142","author":"Takahashi","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.tranon.2018.03.012_bb0165","series-title":"Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma","first-page":"1","author":"TOP","year":"2015"},{"key":"10.1016\/j.tranon.2018.03.012_bb0170","doi-asserted-by":"crossref","first-page":"33035","DOI":"10.18632\/oncotarget.8847","article-title":"High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK\/T cell lymphoma patients","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2018.03.012_bb0175","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin Lymphoma with reduced beta2M\/MHC Class I expression is associated with inferior outcome independent of 9p24.1 Status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.tranon.2018.03.012_bb0180","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2018.03.012_bb0185","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1186\/s13075-015-0859-z","article-title":"Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways","volume":"17","author":"Liu","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.tranon.2018.03.012_bb0190","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s12032-010-9515-2","article-title":"High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation","volume":"28","author":"Mu","year":"2011","journal-title":"Med Oncol"},{"key":"10.1016\/j.tranon.2018.03.012_bb0195","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0611533104","article-title":"Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer","volume":"104","author":"Hamanishi","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tranon.2018.03.012_bb0200","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ejso.2015.01.020","article-title":"The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis","volume":"41","author":"Wang","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.tranon.2018.03.012_bb0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-014-2988-5","article-title":"Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer","volume":"146","author":"Muenst","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.tranon.2018.03.012_bb0210","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.3892\/or.2015.3933","article-title":"The prognostic significance of PD-L1 in bladder cancer","volume":"33","author":"Huang","year":"2015","journal-title":"Oncol Rep"},{"key":"10.1016\/j.tranon.2018.03.012_bb0215","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2015.05.007","article-title":"PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma","volume":"89","author":"Cooper","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2018.03.012_bb0220","series-title":"PD-L1 in renal cell cacinomon prognosis.pdf","first-page":"1","year":"2016"},{"key":"10.1016\/j.tranon.2018.03.012_bb0225","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.21037\/jtd.2016.11.01","article-title":"Clinicopathological and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with esophageal squamous cell carcinoma: a meta-analysis","volume":"8","author":"Qu","year":"2016","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.tranon.2018.03.012_bb0230","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s40880-017-0226-3","article-title":"Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma","volume":"36","author":"Gao","year":"2017","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.tranon.2018.03.012_bb0235","doi-asserted-by":"crossref","first-page":"152","DOI":"10.4132\/jptm.2016.11.03","article-title":"GLUT1 as a prognostic factor for classical Hodgkin's lymphoma: Correlation with PD-L1 and PD-L2 expression","volume":"51","author":"Koh","year":"2017","journal-title":"J Pathol Transl Med"},{"key":"10.1016\/j.tranon.2018.03.012_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166266","article-title":"PD-L1 status in refractory lymphomas","volume":"11","author":"Vranic","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2018.03.012_bb0245","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2018.03.012_bb0250","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00277-015-2403-2","article-title":"Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma","volume":"94","author":"Paydas","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.tranon.2018.03.012_bb0255","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1007\/s13277-015-4622-5","article-title":"Programmed death 1 expression in the peritumoral microenvironment is associated with a poorer prognosis in classical Hodgkin lymphoma","volume":"37","author":"Koh","year":"2016","journal-title":"Tumour Biol"},{"key":"10.1016\/j.tranon.2018.03.012_bb0260","first-page":"1","article-title":"Liquid biopsy: monitoring cancer-genetics in the blood","author":"Crowley","year":"2013","journal-title":"Nat Publ Group"},{"key":"10.1016\/j.tranon.2018.03.012_bb0265","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1872-2075(07)60008-9","article-title":"Preparation and identification of human soluble sPD-L1 and its antibodies","volume":"23","author":"Xu","year":"2007","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"key":"10.1016\/j.tranon.2018.03.012_bb0270","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1039\/C5AN01863C","article-title":"Liquid biopsy for detection of actionable oncogenic mutations in human cancers and electric field induced release and measurement liquid biopsy (eLB)","volume":"141","author":"Tu","year":"2016","journal-title":"Analyst"},{"key":"10.1016\/j.tranon.2018.03.012_bb0275","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1039\/C5AN01762A","article-title":"Isolation and enrichment of circulating biomarkers for cancer screening, detection, and diagnostics","volume":"141","author":"Hyun","year":"2016","journal-title":"Analyst"},{"key":"10.1016\/j.tranon.2018.03.012_bb0280","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrclinonc.2013.110","article-title":"Liquid biopsy: monitoring cancer-genetics in the blood","author":"Crowley","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.tranon.2018.03.012_bb0285","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2567.2007.02723.x","article-title":"Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum","volume":"123","author":"Zhang","year":"2008","journal-title":"Immunology"},{"key":"10.1016\/j.tranon.2018.03.012_bb0290","first-page":"449","article-title":"Effects of soluble programmed death ligand 1 on regulating the proliferation of T lymphocytes and its mechanism","volume":"95","author":"Zhao","year":"2015","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.tranon.2018.03.012_bb0295","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.5301\/jbm.5000170","article-title":"PD-L1 gene polymorphism and high level of plasma soluble PD-L1 protein may be associated with non-small cell lung cancer","volume":"30","author":"Cheng","year":"2015","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.tranon.2018.03.012_bb0300","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1158\/1078-0432.CCR-10-0250","article-title":"Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma","volume":"17","author":"Frigola","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.tranon.2018.03.012_bb0305","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.13578","article-title":"Recent advances in antibody-based therapies for Hodgkin Lymphoma","volume":"171","author":"Peggs","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.tranon.2018.03.012_bb0310","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.tranon.2018.03.012_bb0315","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1345\/aph.1R353","article-title":"Targeted immunotherapy for high-risk neuroblastoma\u2014the role of monoclonal antibodies","volume":"47","author":"Parsons","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.tranon.2018.03.012_bb0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00277-015-2529-2","article-title":"Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy","volume":"95","author":"Adams","year":"2016","journal-title":"Ann Hematol"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523317304357?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523317304357?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:35:28Z","timestamp":1761834928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523317304357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":64,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S1936523317304357"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2018.03.012","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2018.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc. on behalf of SOCIETY. CC BY-NC-ND 4.0","name":"copyright","label":"Copyright"}]}}